Literature DB >> 30551988

Treatment of hypoparathyroidism.

Francesco Tecilazich1, Anna Maria Formenti2, Stefano Frara3, Raffaele Giubbini4, Andrea Giustina5.   

Abstract

The goal of the clinical management of hypoparathyroidism is to correct acute and chronic hypocalcemia. Treatment of acute hypoparathyroidism via intravenous infusion of Ca++ salts, is necessary only in symptomatic patients, or in asymptomatic patients in the setting of a rapid decrease in ionized Ca++ levels. The treatment cornerstones of chronic hypoparathyroidism are oral supplementation of calcium and/or active vitamin D, that can be associated with dietary restriction of sodium and phosphates, thiazide diuretics, and phosphate binders. Notably, PTH replacement is emerging as a innovative treatment of chronic hypoparathyroidism. rhPTH (1-84) has been shown to safely reduce calcium and vitamin D dosage, and increase serum calcium levels in hypoparathyroid patients. Therefore, rhPTH (1-84) appears to represent a new option in patients with chronic hypoparathyroidism "resistant" to conventional treatment.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30551988     DOI: 10.1016/j.beem.2018.12.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  13 in total

Review 1.  Risk of vertebral fractures in hypoparathyroidism.

Authors:  Anna Maria Formenti; Francesco Tecilazich; Raffaele Giubbini; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

2.  Preoperative prophylactic active vitamin D to streamline total thyroidectomy.

Authors:  Matilda Annebäck; Edward McHale Sjödin; Per Hellman; Peter Stålberg; Olov Norlén
Journal:  BJS Open       Date:  2022-05-02

3.  Primary hypoparathyroidism accompanied by rhabdomyolysis induced by infection: A case report.

Authors:  Li-Na Ding; Yi Wang; Jun Tian; Li-Fang Ye; Shi Chen; Shi-Min Wu; Wen-Bin Shang
Journal:  World J Clin Cases       Date:  2019-10-06       Impact factor: 1.337

4.  COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology.

Authors:  M Puig-Domingo; M Marazuela; B O Yildiz; A Giustina
Journal:  Endocrine       Date:  2021-05-08       Impact factor: 3.633

5.  Severe hypocalcemia in a thyroidectomized woman with Covid-19 infection.

Authors:  Simonetta Bossoni; Laura Chiesa; Andrea Giustina
Journal:  Endocrine       Date:  2020-04-28       Impact factor: 3.633

Review 6.  Role of vitamin D in diabetic retinopathy: Pathophysiological and clinical aspects.

Authors:  Francesco Tecilazich; Anna Maria Formenti; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2021-12       Impact factor: 6.514

Review 7.  Challenges in the management of chronic hypoparathyroidism.

Authors:  Guido Zavatta; Bart L Clarke
Journal:  Endocr Connect       Date:  2020-09-01       Impact factor: 3.335

Review 8.  Hypovitaminosis D and the endocrine phenotype of COVID-19.

Authors:  Andrea Giustina
Journal:  Endocrine       Date:  2021-03-18       Impact factor: 3.925

Review 9.  Endocrine and metabolic aspects of the COVID-19 pandemic.

Authors:  Mónica Marazuela; Andrea Giustina; Manuel Puig-Domingo
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

10.  Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19.

Authors:  Luigi Di Filippo; Anna Maria Formenti; Patrizia Rovere-Querini; Michele Carlucci; Caterina Conte; Fabio Ciceri; Alberto Zangrillo; Andrea Giustina
Journal:  Endocrine       Date:  2020-06-12       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.